Drugs / E4
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05460065 | Apr → Sep 2022 | — | NEURALIS s.a. | Terminated | No outcome recorded Stop: Business |
| Phase 21 trial | ||||||
| Phase 2 | NCT03091595 | Feb 2017 → Jun 2018 | — | Estetra | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | E4 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05460065 ↗ |
| Known as | estetrol | “Administration of a single intravenous (i.v.) infusion of estetrol (E4) 28.3 mg (n=6)” NCT05460065 ↗1“15 mg estetrol combined with 3 mg drospirenone” NCT03091595 ↗ |
| Route | Oral | “15 mg E4/3 mg DRSP combined tablets will be administered orally once daily in a 24/4 day regimen for three consecutive cycles” NCT03091595 ↗ |